Clinical Trials Directory

Trials / Completed

CompletedNCT00111995

Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

A Randomized, Double-Blind Study Comparing Aranesp® (Darbepoetin Alfa) and Recombinant Human Erythropoietin (rHuEPO) in the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
400 (planned)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.

Conditions

Interventions

TypeNameDescription
DRUGAranesp®

Timeline

Start date
2002-05-01
First posted
2005-05-30
Last updated
2008-08-08

Source: ClinicalTrials.gov record NCT00111995. Inclusion in this directory is not an endorsement.